October 10, 2019 06:30 AM EDTUpdated 11:28 AM

Wall Street trims cancer drug developer BioNTech's unicorn valuation

Natalie Grover

Reporter

Market conditions in the United States are spooking investors. After ADC Therapeutics rescinded its plans earlier this month for a public listing — citing an adverse …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wall Street trims cancer drug developer BioNTech's unicorn valuation

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Wall Street trims can­cer drug de­vel­op­er BioN­Tech's uni­corn val­u­a­tion

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Wall Street trims cancer drug developer BioNTech's unicorn valuation